Go to deals
Healthcare

Narva clinics has been acquired by Narva Åderbråckscenter AB

The founder and some key employees of Åderbråcksspecialisterna Narva Kirurg Center AB and Narva Derma Center AB (Narva) have completed an MBO.

Åderbråcksspecialisterna Narva Kirurg Center and Narva Derma Center are engaged in varicose vein treatments and aesthetic skincare. Founded in 2012, Narva is a leading Swedish pioneer in modern endovenous treatments for varicose veins. Most of its income comes from private paying patients but Narva is also one of only two market players contracted by the region of Stockholm to carry out varicose vein treatments. Based in Stockholm, Narva also operates several clinics around the country.

Narva Åderbråckscenter AB is a newly created company owned by Narva’s founder together with key employees. The new shareholders will develop Narva’s business plan in order to take advantage of the market opportunities within privately funded healthcare.

Oaklins’ team in Sweden acted as financial advisor in this transaction.

Service
M&A sell-side
Parties
“Together with Oaklins’ team in Sweden, we have carefully worked through the various strategic options at hand for a change of ownership in Narva. The team’s financial and strategic expertise, as well as their experience in the healthcare sector, have been crucial when evaluating the various alternatives.”

Stefan Nydahl

Founder, Narva Åderbråckscenter AB

Talk to the deal team

 Adel  Koubaa

Adel Koubaa

Managing Partner

Stockholm, Sweden
Oaklins Sweden
 Lars  Gustafsson

Lars Gustafsson

Partner

Stockholm, Sweden
Oaklins Sweden

Related deals

Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Learn more
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Learn more